David Brown

The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.

M. Brecher, J. Lindenmayer, D. Meulien, 2008, Psychopharmacology bulletin.

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia

M. Sand, Solen Pichereau, K. Daniels, 2017, Neurology and Therapy.

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

R. Keefe, G. Gründer, J. Cordes, 2017, Schizophrenia bulletin.